Dostarlamab Plus Chemotherapy in Patients With Primary Advanced or Recurrent Endometrial Cancer

Mansour-Raza-Mursa, MD, discussed findings from the interim analysis of the Phase 3 Ruby trial of Dostarlamab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer. Dr. Mursa is Chief Oncologist at Riggs Hospital at Copenhagen University Hospital in Denmark. Ursula Matilonis, Dana-Farber Cancer Institute, Boston Mass., said it's Division Director of Gynecologic Oncology. Can you summarize the purpose and findings of the final overall survival and long-term safety analysis of the NOVA trial?